| 26.2.69
|
CVA Reading 1,p.38, pl. 23., no,11a-b; Lemos 1991 p.303, no.1117, pl.153; Villing et al 2013-2015 (ORC) GD.1215 phase 2;
|
|
| 26.2.72
|
CVA Reading 1,p.38, pl.23, no.14a-b, Lemos 1991 p.131, p.292, no.911, pl.121; Villing et al 2013-2015 (ORC) GD.1212 phase 2;
|
|
| 26.2.80
|
CVA Reading 1,p.38, pl.23, no.16; Villing et al 2013-2015 (ORC) GK.39;
|
|
| 26.2.81
|
CVA Reading 1,p.38, pl. 23, no.17; Villing et al 2013-2015 (ORC) GO.287;
|
|
| 26.2.82
|
CVA Reading 1,p.38, pl. 23.19a-b; Venit 1985 p.395, no.6, Villing et al 2013-2015 (ORC) GC.22 Phase 1, Venit 1982 p.549, no. E7;
|
|
| 26.2.83
|
CVA Reading 1,p.38, pl. 23, no.20a-b; Villing et al 2013-2015 (ORC) GC.26 Phase 1; Venit 1982 p.556, no. E27;
|
|
| 26.2.84
|
CVA Reading 1,p.38, pl. 23, no.21; Villing et al 2013-2015 (ORC) GO.572;
|
|
| 26.2.85
|
CVA Reading 1,p.38, pl. 23, no.22; Villing et al 2013-2015 (ORC) GB.071, Phase 1;
|
|
| 26.2.86
|
CVA Reading 1,p.38, pl. 23, no.23; Villing et al 2013-2015 (ORC) GB.074 Phase 1;
|
|